Anstalt's revenue in the first three quarters of the Chinese region increased by 33.3% year-on-year.

On February 9th, according to the financial report of Astelpharma Group, the operating income for the first 9 months of the 2025 fiscal year was 1.6013 trillion yen, an increase of 10.2% compared to the same period of the previous fiscal year. The core operating profit was 442.1 billion yen, an increase of 48.6% year-on-year. Among them, the revenue from the Chinese business district reached 77.4 billion yen, up by 33.3% year-on-year.